Company intelligence / Profile preview
Pharnext
Paris (Issy-le-Moulineaux), Île-de-France, Francefacebook.com ↗
- Ownership
- Public · ALPHA
- Employees
- ~50
- Development stage
- Phase 3
01
Overview
Pharnext's lead product PXT3003 completed an international Phase III trial with positive topline results for CMT1A and is currently in a pivotal Phase III study called PREMIER. PXT864 has generated encouraging Phase II results in Alzheimer's disease and will be advanced through partnerships.[3]
- Therapeutic areas
- Neurology
- Modalities
- Combination drugsPleodrugs
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Hereditary Neuropathy Foundation (HNF)
04
Financials
- Market cap
- $30B
- Total revenue
- $2.2B
- Enterprise value
- $30.6B
Beyond the preview
Go deeper on Pharnext.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pharnext.